Elicio phase 2 pancreatic cancer trial misses primary endpoint; stock falls 11.9% premarket

Elicio Therapeutics' phase 2 pancreatic cancer trial missed its primary endpoint. The stock fell 11.9% in premarket trading.

Detected & updated continuously · Source: Nebula